Key clinical point: Hypogonadism is a major risk factor for the development of fractures in men and women treated with glucocorticoid (GC).
Major finding: Major risk factors for vertebral fracture were hypogonadism (odds ratio [OR], 12.38; P = .01) and receiving GC boluses (OR 3.45; P = .01) and that for friability fracture were hypogonadism (OR, 7.03; P = .01) and a FRAX index greater than 20 (OR, 7.08; P = .02).
Study details: A cross-sectional study of 127 adults receiving chronic GC treatment for a rheumatological autoimmune disease.
Disclosures: This study was funded in part by the Societat Catalana de Reumatologia. The authors declared no conflicts of interest.
Citation: Florez H et al. RMD Open. 2020 Sep 10. doi: 10.1136/rmdopen-2020-001355 .